Evidence map›Paper›PMID 37835818›Full record

ArticleDiagnostics (Basel, Switzerland)2023

PTOLEMI: Personalized Cancer Treatment through Machine Learning-Enabled Image Analysis of Microfluidic Assays.

Bernard Moerdler, Matan Krasner, Elazar Orenbuch, Avi Grad, Benjamin Friedman, Eliezer Graber, Efrat Barbiro-Michaely, Doron Gerber

Abstract read
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Bernard MoerdlerLife Sciences Faculty and Nanotechnology Institute, Bar-Ilan University, Ramat Gan 5290002, Israel.
Matan KrasnerLife Sciences Faculty and Nanotechnology Institute, Bar-Ilan University, Ramat Gan 5290002, Israel.ORCID 0000-0002-9320-1981
Elazar OrenbuchLife Sciences Faculty and Nanotechnology Institute, Bar-Ilan University, Ramat Gan 5290002, Israel.ORCID 0009-0005-9740-5366
Avi GradLife Sciences Faculty and Nanotechnology Institute, Bar-Ilan University, Ramat Gan 5290002, Israel.
Benjamin FriedmanLife Sciences Faculty and Nanotechnology Institute, Bar-Ilan University, Ramat Gan 5290002, Israel.
Eliezer GraberLife Sciences Faculty and Nanotechnology Institute, Bar-Ilan University, Ramat Gan 5290002, Israel.ORCID 0009-0009-5130-1878
Efrat Barbiro-MichaelyLife Sciences Faculty and Nanotechnology Institute, Bar-Ilan University, Ramat Gan 5290002, Israel.
Doron GerberLife Sciences Faculty and Nanotechnology Institute, Bar-Ilan University, Ramat Gan 5290002, Israel.

Funding

European Commision FET 205761
6 · The paper itself

Abstract

Contemporary personalized cancer diagnostic approaches encounter multiple challenges. The presence of cellular and molecular heterogeneity in patient samples introduces complexities to analysis protocols. Conventional analyses are manual, reliant on expert personnel, time-intensive, and financially burdensome. The copious data amassed for subsequent analysis strains the system, obstructing real-time diagnostics at the "point of care" and impeding prompt intervention. This study introduces PTOLEMI: Python-based Tensor Oncological Locator Examining Microfluidic Instruments. PTOLEMI stands out as a specialized system designed for high-throughput image analysis, particularly in the realm of microfluidic assays. Utilizing a blend of machine learning algorithms, PTOLEMI can process large datasets rapidly and with high accuracy, making it feasible for point-of-care diagnostics. Furthermore, its advanced analytics capabilities facilitate a more granular understanding of cellular dynamics, thereby allowing for more targeted and effective treatment options. Leveraging cutting-edge AI algorithms, PTOLEMI rapidly and accurately discriminates between cell viability and distinct cell types within biopsy samples. The diagnostic process becomes automated, swift, precise, and resource-efficient, rendering it well-suited for point-of-care requisites. By employing PTOLEMI alongside a microfluidic cell culture chip, physicians can attain personalized diagnostic and therapeutic insights. This paper elucidates the evolution of PTOLEMI and showcases its prowess in analyzing cancer patient samples within a microfluidic apparatus. While the integration of machine learning tools into biomedical domains is undoubtedly in progress, this study's innovation lies in the fusion of PTOLEMI with a microfluidic platform-an integrated, rapid, and independent framework for personalized drug screening-based clinical decision-making.

Indexed as

image processingmachine learningmicrofluidicspoint of care diagnostics

Identifiers

PMID37835818
PMCPMC10572730

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.